<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JOCR</journal-id><journal-title-group><journal-title>Journal of Organic Chemistry Research</journal-title></journal-title-group><issn pub-type="epub">2330-5231</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/JOCR.2020.81001</article-id><article-id pub-id-type="publisher-id">JOCR-36515</article-id><article-categories><subj-group subj-group-type="heading"><subject>JOCR20200100000_72289094.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>化学与材料</subject></subj-group></article-categories><title-group><article-title>
 
 
  肿瘤多药耐药机制及化学逆转剂研究进展
  Research Progress of Multidrug Resistance Mechanism and Reverser in Tumor
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>牡丹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胥</surname><given-names>秀英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>豆豆</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>晶晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Andrease</surname><given-names>Melzer</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>一敏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>英国邓迪大学，英国 邓迪</addr-line></aff><aff id="aff2"><addr-line>重庆理工大学药学与生物工程学院，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>07</month><year>2020</year></pub-date><volume>08</volume><issue>01</issue><fpage>1</fpage><lpage>13</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  肿瘤多药耐药(Multidrug Resistance, MDR)系肿瘤细胞对结构与作用靶位不同的抗肿瘤药物产生交叉耐药性的现象，MDR是肿瘤化疗失败的主要原因。本文对肿瘤MDR发生机制及肿瘤MDR化学逆转剂进展进行了综述。
   Multidrug resistance (MDR) is a phenomenon in which tumor cells produce cross-resistance to antitumor drugs with different structures and target targets. MDR is the main reason for the failure of tumor chemotherapy. This article reviews the mechanism of tumor MDR and the progress of tumor MDR chemical reversal agents.
 
</p></abstract><kwd-group><kwd>肿瘤，多药耐药，机制，化学逆转剂, Tumor</kwd><kwd> Multidrug Resistance</kwd><kwd> Mechanism</kwd><kwd> Chemical Reversal Agent</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>肿瘤多药耐药机制及化学逆转剂研究进展<sup> </sup></title><p>郭牡丹<sup>1</sup>，胥秀英<sup>1</sup>，徐豆豆<sup>1</sup>，刘晶晶<sup>1</sup>，Andrease Melzer<sup>2</sup>，郑一敏<sup>1*</sup></p><p><sup>1</sup>重庆理工大学药学与生物工程学院，重庆</p><p><sup>2</sup>英国邓迪大学，英国 邓迪</p><p>收稿日期：2020年6月24日；录用日期：2020年7月8日；发布日期：2020年7月15日</p><disp-formula id="hanspub.36515-formula3"><graphic xlink:href="//html.hanspub.org/file/1-2970145x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>肿瘤多药耐药(Multidrug Resistance, MDR)系肿瘤细胞对结构与作用靶位不同的抗肿瘤药物产生交叉耐药性的现象，MDR是肿瘤化疗失败的主要原因。本文对肿瘤MDR发生机制及肿瘤MDR化学逆转剂进展进行了综述。</p><p>关键词 :肿瘤，多药耐药，机制，化学逆转剂</p><disp-formula id="hanspub.36515-formula4"><graphic xlink:href="//html.hanspub.org/file/1-2970145x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2970145x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2970145x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肿瘤严重威胁人类生命和健康 [<xref ref-type="bibr" rid="hanspub.36515-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref3">3</xref>]，目前90%以上肿瘤患者治疗失败都与肿瘤MDR有关 [<xref ref-type="bibr" rid="hanspub.36515-ref3">3</xref>]。本文对肿瘤MDR发生机制以及逆转肿瘤MDR的进展进行了综述。</p></sec><sec id="s4"><title>2. 多药耐药机制</title><p>肿瘤细胞MDR形成机制是多因素参与的复杂过程，ABC转运蛋白家族、miRNA、肿瘤干细胞(cancer stem cell, CSC)、自噬诱导、诱导异常、DNA损伤修复、药物靶点突变及表观遗传诱导与之有关(图1)。</p><p>图1. 肿瘤MDR潜在机制 [<xref ref-type="bibr" rid="hanspub.36515-ref4">4</xref>]</p><sec id="s4_1"><title>2.1. ABC转运蛋白家族</title><p>ABC转运蛋白能外排细胞内药物，分ABCA到ABCG亚家族 [<xref ref-type="bibr" rid="hanspub.36515-ref5">5</xref>]，共49种不同类型的转运蛋白 [<xref ref-type="bibr" rid="hanspub.36515-ref6">6</xref>]。如ABCB1促使癌细胞对米托蒽醌，沙奎那韦，表鬼臼毒素和蒽环类药物的耐药性 [<xref ref-type="bibr" rid="hanspub.36515-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref10">10</xref>]。ABCG2与乳腺癌、结肠癌、胃癌、小细胞肺癌和卵巢癌MDR关系密切 [<xref ref-type="bibr" rid="hanspub.36515-ref11">11</xref>]。ABC转运蛋白已经成为开发新型逆转剂的靶点 [<xref ref-type="bibr" rid="hanspub.36515-ref12">12</xref>]。</p></sec><sec id="s4_2"><title>2.2. miRNA调控</title><p>miRNA是一类小非编码RNA，它通过调节ABC转运蛋白，凋亡蛋白，DNA损伤修复，自噬和药物代谢酶等(图2)产生肿瘤MDR [<xref ref-type="bibr" rid="hanspub.36515-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref14">14</xref>]。</p><p>图2. miRNA调控肿瘤细胞MDR路径 [<xref ref-type="bibr" rid="hanspub.36515-ref15">15</xref>]</p></sec><sec id="s4_3"><title>2.3. 肿瘤干细胞(CSC)调控</title><p>CSC具有自我更新和分化特性，多处于细胞G0期，具有很高的端粒酶活性及DNA复制修复能力，是造成肿瘤耐药的最根本原因 [<xref ref-type="bibr" rid="hanspub.36515-ref16">16</xref>]。通过高表达ABC转运蛋白和抗凋亡基因而逃避化疗及放疗，导致肿瘤复发和转移 [<xref ref-type="bibr" rid="hanspub.36515-ref17">17</xref>]。</p></sec><sec id="s4_4"><title>2.4. 自噬诱导</title><p>自噬是一个高度保守的细胞降解和循环过程 [<xref ref-type="bibr" rid="hanspub.36515-ref18">18</xref>]。自噬通过降解药物分子发挥其细胞保护作用，帮助癌细胞逃避凋亡 [<xref ref-type="bibr" rid="hanspub.36515-ref19">19</xref>]。</p></sec><sec id="s4_5"><title>2.5. 凋亡异常</title><p>肿瘤细胞通过抑制细胞凋亡而引起MDR [<xref ref-type="bibr" rid="hanspub.36515-ref20">20</xref>]。肿瘤细胞凋亡异常有凋亡蛋白抑制因子、Caspase-8蛋白、死亡受体等表达异常 [<xref ref-type="bibr" rid="hanspub.36515-ref21">21</xref>]。</p></sec><sec id="s4_6"><title>2.6. DNA损伤和修复(DDR)</title><p>肿瘤细胞DNA修复可以切除抗肿瘤药物致命性的DNA损伤，降低基于破坏肿瘤细胞DNA药物的效果。最新研究表明，在10,489例肿瘤内，80个核心DDR基因中有13个被显著扩增和过表达，带有DDR基因扩增的肿瘤可产生化疗耐药而导致整体生存率下降 [<xref ref-type="bibr" rid="hanspub.36515-ref22">22</xref>]。</p></sec><sec id="s4_7"><title>2.7. 表观遗传诱导</title><p>表观遗传是指细胞内除遗传信息以外的其他可遗传物质的改变，与肿瘤MDR的恶性表型密切 [<xref ref-type="bibr" rid="hanspub.36515-ref23">23</xref>]。</p></sec></sec><sec id="s5"><title>3. 化学逆转剂</title><sec id="s5_1"><title>3.1. 临床研究中逆转肿瘤MDR药物</title><sec id="s5_1_1"><title>3.1.1. 靶向ABCB1耐药逆转剂</title><p>靶向ABCB1/p-gp/MDR1耐药逆转剂(图3)经历了三代发展(表1)，目前已经研发至第四代。由于毒副作用大，至今没有应用于临床。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Targeted ABCB1 resistance reversal agent</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分类</th><th align="center" valign="middle" >代表化合物</th><th align="center" valign="middle" >问题</th></tr></thead><tr><td align="center" valign="middle" >第一代 [<xref ref-type="bibr" rid="hanspub.36515-ref24">24</xref>]</td><td align="center" valign="middle" >维拉帕米(Verapamil)和环孢素A</td><td align="center" valign="middle" >治疗效果差、所需剂量高、易产生心脏毒副作用</td></tr><tr><td align="center" valign="middle" >第二代 [<xref ref-type="bibr" rid="hanspub.36515-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref26">26</xref>]</td><td align="center" valign="middle" >右旋维拉帕米(dexverapamil)、哌啶类衍生物VX-710、环孢素A的同系物PSC833</td><td align="center" valign="middle" >选择性差，抑制CYP450介导的抗癌药物代谢， 干扰正常细胞代谢，仍存在毒副作用</td></tr><tr><td align="center" valign="middle" >第三代 [<xref ref-type="bibr" rid="hanspub.36515-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref28">28</xref>]</td><td align="center" valign="middle" >环丙基二苯并环庚烷类物质[Zosuquidar (LY335979)，Laniquidar (R101933)]、新型氨基哌啶类逆转剂S9788</td><td align="center" valign="middle" >在一定程度上克服了前两代的不足之处， 但仍然存在药代动力学异常、对正常细胞毒性大等问题</td></tr></tbody></table></table-wrap><p>表1. 靶向ABCB1耐药逆转剂</p><p>图3. 靶向ABCB1耐药逆转剂</p></sec><sec id="s5_1_2"><title>3.1.2 谷胱甘肽转移酶(GST)/谷胱甘肽(GSH)抑制剂</title><p>GST/GSH过度表达而产生MDR [<xref ref-type="bibr" rid="hanspub.36515-ref29">29</xref>]。抑制GSH的药物有丁硫氨酸亚碘胺(BSO)、依地尼酸(EA)、硝基咪哇类等。BSO是谷氨酰半胱氨酸合成酶的特异性抑制剂，它通过降低细胞内GSH的浓度，增加肿瘤细胞对抗癌药物的敏感性逆转MDR。EA可以抑制GST的活性，在GST的催化作用下，EA与GSH结合形成的EA-GSH复合物比EA更强作用 [<xref ref-type="bibr" rid="hanspub.36515-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref30">30</xref>]。小分子化合物APR-246 (图4)具有调节细胞内GSH水平的作用，毒副作用小，是潜在的MDR逆转剂，正在进行临床试验 [<xref ref-type="bibr" rid="hanspub.36515-ref31">31</xref>]。</p></sec><sec id="s5_1_3"><title>3.1.3. 拓扑异构酶(Topo)抑制剂</title><p>Topo是细胞凋亡过程中关键的核内酶。临床用药初期，TopoI抑制剂(伊立替康、拓扑替康等)抗肿瘤敏感性较高，但易产生耐药性。TopoII抑制剂XR11576 (图5)可逆转TopoI/ABCB1/MRP导致的MDR [<xref ref-type="bibr" rid="hanspub.36515-ref32">32</xref>]，目前在I期临床研究中。TopoI和TopoII抑制剂联合使用可产生一加一大于二的协同作用，达到逆转MDR的效果，国内外已进入临床实验 [<xref ref-type="bibr" rid="hanspub.36515-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref35">35</xref>]。</p><p>图4. APR-246结构式</p><p>图5. XR11576</p></sec><sec id="s5_1_4"><title>3.1.4. 酪氨酸激酶抑制剂(TKIs)</title><p>TKIs (图6)抑制ABC转运蛋白活性，逆转肿瘤细胞对一些传统化疗药物的MDR。如伊马替尼(Imatinib)可逆转ABCB1过度表达的表皮癌细胞系(KB-G2)对长春新碱、紫杉醇、依托泊苷的耐药性 [<xref ref-type="bibr" rid="hanspub.36515-ref29">29</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref36">36</xref>]，尼洛替尼(Nilotinib)逆转ABCC1介导的肿瘤多药耐药，但会改变传统抗癌药物的血药动力学，不宜用于临床。厄洛替尼联合曲妥珠单抗表现出较好的耐受性和增强抗肿瘤活性，联合化疗治疗MDR患者值得进一步临床研究 [<xref ref-type="bibr" rid="hanspub.36515-ref37">37</xref>]。</p><p>达沙替尼(Dasatinib)属第二代酪氨酸激酶抑制剂，用于已经治疗，包括甲磺酸伊马替耐药或不能耐受的慢性骨髓性白血病所有病期的成人患者，不良反应大部分轻度到中度 [<xref ref-type="bibr" rid="hanspub.36515-ref38">38</xref>]。</p><p>奥西替尼(Oxitinib)是第三代不可逆的口服EGFR-TKI，可以有效和选择性地抑制EGFR敏感突变和EGFR T790M耐药突变，MET扩增是EGFR-TKI产生MDR原因之一，临床前研究和初步临床资料表明，联合使用MET抑制剂和EGFR-TKI是治疗EGFR-TKIs获得性耐药的有效方法 [<xref ref-type="bibr" rid="hanspub.36515-ref39">39</xref>]。</p></sec><sec id="s5_1_5"><title>3.1.5. 其它</title><p>蛋白激酶C(PKC)可以改变药物在MDR细胞中的蓄积，部分MDR肿瘤细胞中PKC活性增加。</p><p>图6. TKIs抑制剂</p><p>CGP41251 (图7)是高度选择性的PKC抑制剂，具有抗肿瘤及有效逆转MDR的作用，使MDR细胞对阿霉素和长春新碱的敏感性增加。然而，由于它逆转MDR的同时也产生较大的毒性作用，限制了临床应用 [<xref ref-type="bibr" rid="hanspub.36515-ref40">40</xref>]。GS-4997 (图7)是一种凋亡信号调节激酶1 (ASK1)抑制剂，处于III期临床试验中，研究发现GS-4997可以抑制肿瘤MDR细胞中ABCB1和ABCG2的表达，提示GS-4997有希望发展MDR逆转剂 [<xref ref-type="bibr" rid="hanspub.36515-ref41">41</xref>]。</p><p>图7. CGP41251和GS-4997</p></sec></sec><sec id="s5_2"><title>3.2. 逆转肿瘤MDR临床前研究药物</title><p>论当前逆转肿瘤MDR临床前研究药物结构见图8，进展见表2。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Drugs that reverse tumor MDR preclinical researc</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >分类</th><th align="center" valign="middle" >代表化合物</th><th align="center" valign="middle" >研究情况</th></tr></thead><tr><td align="center" valign="middle" >ABCB1抑制剂</td><td align="center" valign="middle" >NFV</td><td align="center" valign="middle" >降低MDR细胞内ATP含量，促进K562/ADR细胞凋亡，逆转MDR， 后续需进行动物和临床MDR研究 [<xref ref-type="bibr" rid="hanspub.36515-ref42">42</xref>]</td></tr><tr><td align="center" valign="middle" >ABCG2抑制剂</td><td align="center" valign="middle" >FTC, Ko143</td><td align="center" valign="middle" >FTC存在严重中枢神经系统毒性，未进行进一步临床研究； Ko143比FITC毒性小，动物实验表明Ko143可逆转ABCG2介导的MDR [<xref ref-type="bibr" rid="hanspub.36515-ref43">43</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref44">44</xref>]</td></tr><tr><td align="center" valign="middle" >src家族激酶抑制剂</td><td align="center" valign="middle" >A-770041</td><td align="center" valign="middle" >抑制Src和Lck的激活和表达，逆转骨肉瘤细胞对紫杉醇和阿霉素的MDR， 其逆转机制有待进一步研究 [<xref ref-type="bibr" rid="hanspub.36515-ref45">45</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >c-Met激酶抑制剂</th><th align="center" valign="middle" >PHA-665752</th><th align="center" valign="middle" >PHA-665752通过抑制PI3K-Akt信号传导， 再抑制c-Met活化可使骨肉瘤细胞对顺铂敏感 [<xref ref-type="bibr" rid="hanspub.36515-ref46">46</xref>]</th></tr></thead><tr><td align="center" valign="middle" >ALK抑制剂</td><td align="center" valign="middle" >NVP-TAE684</td><td align="center" valign="middle" >作为治疗难治愈和复发的ALK阳性淋巴癌的一种策略，未进行临床实验； 通过刺激ABCB1 ATP酶活性来抑制ABCB1的表达， 提示NVP-TAE684是ABCB1介导MDR的研究方向 [<xref ref-type="bibr" rid="hanspub.36515-ref47">47</xref>]</td></tr><tr><td align="center" valign="middle" >BCL-2抑制剂</td><td align="center" valign="middle" >Venetoclax</td><td align="center" valign="middle" >增加了化疗药在MDR细胞内积累， venetoclax是联合治疗中克服ABCG2介导的MDR的有效策略 [<xref ref-type="bibr" rid="hanspub.36515-ref48">48</xref>]</td></tr><tr><td align="center" valign="middle" >其它</td><td align="center" valign="middle" >Ethaselen, RAL</td><td align="center" valign="middle" >Ethaselen与某些化疗药物相结合，具有致敏化合物的功效 [<xref ref-type="bibr" rid="hanspub.36515-ref49">49</xref>] ； RAL体外试验表明可增强ER-MDR乳腺肿瘤对紫杉醇的敏感性 [<xref ref-type="bibr" rid="hanspub.36515-ref50">50</xref>]</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 逆转肿瘤MDR临床前研究药物</p><p>图8. 逆转肿瘤MDR临床前研究药物</p></sec><sec id="s5_3"><title>3.3. 逆转肿瘤MDR先导化合物</title><sec id="s5_3_1"><title>3.3.1. 天然先导化合物</title><p>以查耳酮、7-异戊烯氧基香豆素(7-IP)和麻疯树二萜类天然产物为先导合成的化合物(图9)具有良好的MDR逆转效果(表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Lead compounds derived from natural product</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >先导化合物</th><th align="center" valign="middle" >合成产物</th><th align="center" valign="middle" >最优逆转MDR产物</th><th align="center" valign="middle" >研究情况</th></tr></thead><tr><td align="center" valign="middle" >查耳酮 [<xref ref-type="bibr" rid="hanspub.36515-ref51">51</xref>]</td><td align="center" valign="middle" >B环上被喹喔啉单元取代衍生物</td><td align="center" valign="middle" >化合物1和2</td><td align="center" valign="middle" >逆转ABCG2介导的米托蒽醌外排。 B环4位的取代是关键， 在该位置，O-苄基残基是抑制ABCG2最有效的取代基</td></tr><tr><td align="center" valign="middle" >7-IP [<xref ref-type="bibr" rid="hanspub.36515-ref52">52</xref>] [<xref ref-type="bibr" rid="hanspub.36515-ref53">53</xref>]</td><td align="center" valign="middle" >含有7-IP核的丁炔基–氨基链衍生物</td><td align="center" valign="middle" >化合物1e</td><td align="center" valign="middle" >无剂量依赖性，其逆转特性与丁炔基-氨基侧链有关， 特别是端胺是逆转肿瘤MDR的关键特征</td></tr><tr><td align="center" valign="middle" >麻疯树二萜类 [<xref ref-type="bibr" rid="hanspub.36515-ref54">54</xref>]</td><td align="center" valign="middle" >通过结构修饰产生了22种新的衍生物</td><td align="center" valign="middle" >化合物19、25、26</td><td align="center" valign="middle" >化合物26有更大的MDR逆转能力和更低细胞毒性， 对其进一步的评价和结构修饰具有重要意义</td></tr></tbody></table></table-wrap><p>表3. 来源于天然产物的先导化合物</p><p>图9. 以天然产物为先导合成的化合物</p></sec><sec id="s5_3_2"><title>3.3.2. 合成先导化合物</title><p>近年来化学合成的LS-2-3j、479、C4、D3和D6先导化合物结构见图10，进展见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Lead compound from chemical synthesi</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >合成类别</th><th align="center" valign="middle" >先导化合物</th><th align="center" valign="middle" >研究情况</th></tr></thead><tr><td align="center" valign="middle" >新型二氢茚并[1,2-b]吲哚衍生物 [<xref ref-type="bibr" rid="hanspub.36515-ref55">55</xref>]</td><td align="center" valign="middle" >LS-2-3j</td><td align="center" valign="middle" >下调ABCB1和ABCG2的mRNA和蛋白表达水平，增强MDR细胞中DOX和MITX的蓄积，逆转MDR；可用作肿瘤MDR药物发现和开发的先导化合物</td></tr><tr><td align="center" valign="middle" >新型5-氰基-6-苯基嘧啶衍生物 [<xref ref-type="bibr" rid="hanspub.36515-ref56">56</xref>]</td><td align="center" valign="middle" >479</td><td align="center" valign="middle" >逆转ABCB1和ABCG2介导的MDR方面表现出选择性双重活性， 是设计和开发双目标MDR逆转剂的先导化合物。</td></tr><tr><td align="center" valign="middle" >十二种新颖的5-氧代六氢喹啉衍生物 [<xref ref-type="bibr" rid="hanspub.36515-ref57">57</xref>]</td><td align="center" valign="middle" >C4、D3、D6</td><td align="center" valign="middle" >评估了对耐药性人子宫肉瘤细胞系(MES-SA/DX5˚)的逆转作用， 发现C4，D3和D6能够同时阻断3种参与MDR的转运蛋白，在此基础上， 进一步合成改造，有希望发现克服MDR药物</td></tr></tbody></table></table-wrap><p>表4. 来源于化学合成的先导化合物</p><p>图10. 化学合成的先导化合物</p></sec></sec></sec><sec id="s6"><title>4. 结语与展望</title><p>肿瘤MDR是肿瘤治疗失败主要原因，明确MDR机制，联合用药是克服肿瘤MDR的有效手段。目前化学逆转剂毒副作用限制了临床应用，开发高效低毒的靶向药物是当务之急，先导化合物的发现与结构优化是主要努力方向之一，有望开发理想的MDR逆转剂。</p></sec><sec id="s7"><title>基金项目</title><p>国家高端外国专家项目(GDW20155200280)。</p></sec><sec id="s8"><title>文章引用</title><p>郭牡丹,胥秀英,徐豆豆,刘晶晶,Andrease Melzer,郑一敏. 肿瘤多药耐药机制及化学逆转剂研究进展Research Progress of Multidrug Resistance Mechanism and Reverser in Tumor[J]. 有机化学研究, 2020, 08(01): 1-13. https://doi.org/10.12677/JOCR.2020.81001</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.36515-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Markman, J.L., Rekechenetskiy, A., Holler, E., et al. (2018) Nanomedicine Therapeutic Approaches to Overcome Cancer Drug Resistance. Advanced Drug Delivery Reviews, 65, 1866-879. &lt;br&gt;https://doi.org/10.1016/j.addr.2013.09.019</mixed-citation></ref><ref id="hanspub.36515-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancer in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
&lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.36515-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, D., Chen, Q., Song, H., et al. (2018) Theranostic Micelles Combined with Multiple Strategies to Effectively Overcome Multidrug Resistance. Nanomedicine, 13, 1517-1533. &lt;br&gt;https://doi.org/10.2217/nnm-2017-0393</mixed-citation></ref><ref id="hanspub.36515-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Q., Yang, Z., Nie, Y., Shi, Y., et al. (2014) Multi-Drug Re-sistance in Cancer Chemotherapeutics: Mechanisms and Lab Approaches. Cancer Letters, 347, 159-166. &lt;br&gt;https://doi.org/10.1016/j.canlet.2014.03.013</mixed-citation></ref><ref id="hanspub.36515-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, P., Zhang, D.M., Degenhardt, K. and Chen, Z.S. (2012) Autophagy and Transporter Based Multi-Drug Resistance. Cells, 1, 558-575. &lt;br&gt;https://doi.org/10.3390/cells1030558</mixed-citation></ref><ref id="hanspub.36515-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kathawala, R.J., Wang, Y.J., Ashby Jr., C.R., et al. (2014) Recent Ad-vances Regarding the Role of ABC Subfamily C Member 10 (ABCC10) in the Efflux of Antitumor Drugs. Chinese Journal of Cancer, 33, 223-230.  
&lt;br&gt;https://doi.org/10.5732/cjc.013.10122</mixed-citation></ref><ref id="hanspub.36515-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Nabekura, T., Kawasaki, T., Furuta, M., et al. (2018) Effects of Natural Polyphenols on the Expression of Drug Efflux Transporter P-Glycoprotein in Human Intestinal Cells. ACS Omega, 3, 1621-1626.  
&lt;br&gt;https://doi.org/10.1021/acsomega.7b01679</mixed-citation></ref><ref id="hanspub.36515-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Festa, L., Roth, L.M., Jensen, B.K., et al. (2019) Protease Inhib-itors, Saquinavir and Darunavir, Inhibit Oligodendrocyte Maturation: Implications for Lysosomal Stress. Journal of Neuroimmune Pharmacology.  
&lt;br&gt;https://doi.org/10.1007/s11481-019-09893-8</mixed-citation></ref><ref id="hanspub.36515-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Anreddy, N., Gupta, P., Kathawala, R.J., et al. (2014) Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules, 19, 13848-13877. &lt;br&gt;https://doi.org/10.3390/molecules190913848</mixed-citation></ref><ref id="hanspub.36515-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">de Klerk, D.J., Honeywell, R.J., Jansen, G. and Peters, G.J. (2018) Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strat-egies to Overcome Resistance. Cancers (Basel), 10, 503.</mixed-citation></ref><ref id="hanspub.36515-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chun, S.Y., Kwon, Y.S., Nam, K.S. and Kim, S. (2015) Lapatinib Enhances the Cytotoxic Effects of Doxorubicin in MCF-7 Tumorspheres by Inhibiting the Drug Efflux Function of ABC Transporters. Biomedicine &amp; Pharmacotherapy, 72, 37-43. &lt;br&gt;https://doi.org/10.1016/j.biopha.2015.03.009</mixed-citation></ref><ref id="hanspub.36515-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, G.N., Ashby, C.R., Zhang, Y.K., et al. (2015) The Re-versal of Antineoplastic Drug Resistance in Cancer Cells by β-Elemene. Chinese Journal of Cancer, 34, Article No.: 45. &lt;br&gt;https://doi.org/10.1186/s40880-015-0048-0</mixed-citation></ref><ref id="hanspub.36515-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S.-N., Chang, R., Lin, L.-T., et al. (2019) MicroRNA in Ovarian Cancer: Biology, Pathogenesis, and Therapeutic Opportunities. International Journal of Environmental Research &amp; Public Health, 16, 1510.</mixed-citation></ref><ref id="hanspub.36515-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, T., Wang, J., Chen, X., et al. (2010) Role of microRNA in Anticancer Drug Resistance. International Journal of Cancer, 126, 2-10. &lt;br&gt;https://doi.org/10.1002/ijc.24782</mixed-citation></ref><ref id="hanspub.36515-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Liao, R.R., Lin, Y.X. and Zhu, L.H. (2018) Molecular Pathways Involved in microRNA-Mediated Regulation of Multidrug Resistance. Molecular Biology Reports, 45, 2913-2923.</mixed-citation></ref><ref id="hanspub.36515-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">修一冉, 马秀梅. 肿瘤干细胞标志物研究进展[J]. 世界最新医学信息文摘, 2018, 18(A5): 75-77, 79.</mixed-citation></ref><ref id="hanspub.36515-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王纪珍, 陈君敏, 曾志勇, 等. 自噬调节药物对多发性骨髓瘤细胞增殖、凋亡和自噬的影响[J]. 中国实验血液学杂志, 2018(3): 817-823.</mixed-citation></ref><ref id="hanspub.36515-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">徐桂芳, 张伟杰, 周志华. 肿瘤干细胞与多药耐药[J]. 国际肿瘤学杂志, 2012, 39(12): 902-904.</mixed-citation></ref><ref id="hanspub.36515-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Vinod, B.S., Maliekal, T.T. and Anto, R.J. (2013) Phytochemicals as Chemosensitizers: From Molecular Mechanism to Clinical Significance. Antioxidants &amp; Redox Signaling, 18, 1307-1348. &lt;br&gt;https://doi.org/10.1089/ars.2012.4573</mixed-citation></ref><ref id="hanspub.36515-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">谭川, 黄杰. 肺癌患者外周血miR-214表达及对肺癌细胞凋亡和多药耐药的影响[J]. 中华实用诊断与治疗杂志, 2019(11): 1073-1077.</mixed-citation></ref><ref id="hanspub.36515-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">孙晓冉, 孙剑经, 张林西. 肿瘤多药耐药机制的研究进展[J]. 现代肿瘤医学, 2017(1): 169-171.</mixed-citation></ref><ref id="hanspub.36515-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Z., Li, S., Tang, X., Wang, Y., et al. (2020) Copy Number Amplification of DNA Damage Repair Pathways Potentiates Therapeutic Resistance in Cancer. Theranostics, 10, 3939-3951. &lt;br&gt;https://doi.org/10.7150/thno.39341</mixed-citation></ref><ref id="hanspub.36515-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">郭姗琦, 赵海丰, 张翼鷟. 恶性淋巴瘤的表观遗传调控与治疗[J]. 中华肿瘤杂志, 2014, 36(3): 161-164.</mixed-citation></ref><ref id="hanspub.36515-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Nobili, S., Landini, I., Mazzei, T., et al. (2012) Overcoming Tumor Multidrug Resistance Using Drugs Able to Evade P-Glycoprotein or to Exploit Its Expression. Medicinal Research Reviews, 32, 1220-1262.  
&lt;br&gt;https://doi.org/10.1002/med.20239</mixed-citation></ref><ref id="hanspub.36515-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Duran, G.E., Derdau, V., Weitz, D., et al. (2018) Cabazitaxel Is More Ac-tive than First-Generation Taxanes in ABCB1(+) Cell Lines Due to Its Reduced Affinity for P-Glycoprotein. Cancer Chemotherapy &amp; Pharmacology, 81, 1095-1103.  
&lt;br&gt;https://doi.org/10.1007/s00280-018-3572-1</mixed-citation></ref><ref id="hanspub.36515-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lhommé, C., Joly, F., Walker, J.L., et al. (2008) Phase III Study of Valspodar (PSC 833) Combined with Paclitaxel and Carboplatin Compared with Paclitaxel and Carboplatin Alone in Patients with Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer. Journal of Clinical Oncology, 26, 2674-2682.  
&lt;br&gt;https://doi.org/10.1200/JCO.2007.14.9807</mixed-citation></ref><ref id="hanspub.36515-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Karbanova, S., Cerveny, L., Jiraskova, L., et al. (2019) Transport of Ribavirin across the Rat and Human Placental Barrier: Roles of Nucleoside and ATP-Binding Cassette Drug Efflux Transporters. Biochemical Pharmacology, 163, 60-70. &lt;br&gt;https://doi.org/10.1016/j.bcp.2019.01.024</mixed-citation></ref><ref id="hanspub.36515-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Cui, Q.B., Wang, J.-Q., Assaraf, Y.G., et al. (2018) Modulating ROS to Overcome Multidrug Resistance in Cancer. Drug Re-sistance Updates: Reviews &amp;Commentaries in Antimicrobial &amp; Anticancer Chemotherapy, 41, 1-25.</mixed-citation></ref><ref id="hanspub.36515-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">张游华, 顾轫赜, 牛天力, 等. DNA拓扑异构酶抑制剂在逆转肿瘤多药耐药性中的研究进展[J]. 现代肿瘤医学, 2016(24): 4033.</mixed-citation></ref><ref id="hanspub.36515-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Miyahara, D., Ueda, T., Katsuda, T., et al. (2015) The Safety of Pegylated Liposomal Doxorubicin plus Irinotecan in Recurrent Ovarian Cancer Patients: A Phase I Trial. Anticancer Res, 35, 4521-4525.</mixed-citation></ref><ref id="hanspub.36515-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Peng, X., Zhang, M.Q.Z., Conserva, F., et al. (2013) APR-246/PRIMA-1MET Inhibits Thioredoxinreductase1 and Converts the Enzyme to a Dedicated NADPH Oxidase. Cell Death &amp; Disease, 4, e881.  
&lt;br&gt;https://doi.org/10.1038/cddis.2013.417</mixed-citation></ref><ref id="hanspub.36515-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Ding, X. and Matsuo, K. (2015) Optimized Combinations of Borte-zomib, Camptothecin, and Doxorubicin Show Increased Efficacy and Reduced Toxicity in Treating Oral Cancer. An-ti-Cancer Drugs, 26, 547-554.  
&lt;br&gt;https://doi.org/10.1097/CAD.0000000000000222</mixed-citation></ref><ref id="hanspub.36515-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Peleg, R., Romzova, M., Kogan-Zviagin, I., et al. (2014) Modification of Topoisomerases in Mammospheres Derived from Breast Cancer Cell Line: Clinical Implications for Combined Treatments with Tyrosine Kinase Inhibitors. BMC Cancer, 14, Article No.: 910. &lt;br&gt;https://doi.org/10.1186/1471-2407-14-910</mixed-citation></ref><ref id="hanspub.36515-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Ullah, M.F., Bhat, S.H. and Abuduhier, F.M. (2016) Dietary Factors May Influence the Clinical Outcome of Chemotherapy in Cancer Multidrug Resistance. In: Ullah, M. and Ahmad, A., Eds., Critical Dietary Factors in Cancer Chemoprevention, Springer, Cham, 307-319. &lt;br&gt;https://doi.org/10.1007/978-3-319-21461-0_15</mixed-citation></ref><ref id="hanspub.36515-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Niki, K., Chara, P., Eleni, L., et al. (2013) Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide. PLoS ONE, 8, e74611. &lt;br&gt;https://doi.org/10.1371/journal.pone.0074611</mixed-citation></ref><ref id="hanspub.36515-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Fang, Z., Chen, W., Yuan, Z., et al. (2018) LncRNA-MALAT1 Contributes to the Cisplatin-Resistance of Lung Cancer by Upregulating MRP1 and MDR1 via STAT3 Activation. Biomedicine &amp; Pharmacotherapy, 101, 536-542.  
&lt;br&gt;https://doi.org/10.1016/j.biopha.2018.02.130</mixed-citation></ref><ref id="hanspub.36515-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Ji, G., Zhang, C., Guan, S., et al. (2018) Erlotinib for Progres-sive Brain and Leptomeningeal Metastases from HER2- Positive Breast Cancer after Treatment Failure with Trastuzumab and Lapatinib: Experience and Review of Literature. Clinical Breast Cancer, 18, e759-e765. &lt;br&gt;https://doi.org/10.1016/j.clbc.2018.07.022</mixed-citation></ref><ref id="hanspub.36515-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">胡敏, 袁凯锋, 李晓明, 等. 伊马替尼、尼洛替尼和达沙替尼对慢性粒细胞白血病慢性期患者的临床疗效[J]. 中国临床药理学杂志, 2016(6): 511-513.</mixed-citation></ref><ref id="hanspub.36515-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Martinez-Marti, A., Felip, E., Matito, J., et al. (2017) Dual MET and ERBB Inhibition Overcomes Intratumor Plasticity in Osimer-tinib-Resistant-Advanced Non-Small-Cell Lung Cancer (NSCLC). Annals of Oncology, 28, 2451-2457.  
&lt;br&gt;https://doi.org/10.1093/annonc/mdx396</mixed-citation></ref><ref id="hanspub.36515-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Kim, C.W., Asai, D., Kang, J.H., et al. (2016) Reversal of Efflux of an Anticancer Drug in Human Drug-Resistant Breast Cancer Cells by Inhibition of Protein Kinase Cα (PKCα) Activity. Tumor Biology, 37, 1901-1908.  
&lt;br&gt;https://doi.org/10.1007/s13277-015-3963-4</mixed-citation></ref><ref id="hanspub.36515-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Ji, N., Yang, Y., Cai, C.Y., et al. (2018) Selonsertib (GS-4997), an ASK1 Inhibitor, Antagonizes Multidrug Resistance in ABCB1 and ABCG2 Overexpressing Cancer Cells. Cancer Letters, 440-441, 82-93.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2018.10.007</mixed-citation></ref><ref id="hanspub.36515-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Liu, W., Meng, Q., Sun, Y., et al. (2018) Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells. Cellular Physiology and Biochemistry, 51, 1616-1631. &lt;br&gt;https://doi.org/10.1159/000495650</mixed-citation></ref><ref id="hanspub.36515-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Takeda, N., Furuishi, M., Nishijima, Y., et al. (2018) Chiral Isoxazolidine-Mediated Stereoselective Umpolung α-Pheny- lation of Methyl Ketones. Organic &amp; Biomolecular Chemistry, 16, 8940-8943. &lt;br&gt;https://doi.org/10.1039/C8OB02480D</mixed-citation></ref><ref id="hanspub.36515-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Yang, C.E., Lee, W.Y., Cheng, H.W., et al. (2019) The Antipsychotic Chlorpromazine Suppresses YAP Signaling, Stemness Properties, and Drug Resistance in Breast Cancer Cells. Chemico-Biological Interactions, 302, 28-35.  
&lt;br&gt;https://doi.org/10.1016/j.cbi.2019.01.033</mixed-citation></ref><ref id="hanspub.36515-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Duan, Z., Zhang, J., Ye, S., Shen, J., et al. (2014) A-770041 Re-verses Paclitaxel and Doxorubicin Resistance in Osteosarcoma Cells. BMC Cancer, 14, Article No.: 681. &lt;br&gt;https://doi.org/10.1186/1471-2407-14-681</mixed-citation></ref><ref id="hanspub.36515-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Wang, K., Zhuang, Y., Liu, C., et al. (2012) Inhibition of c-Met Activation Sensitizes Osteosarcoma Cells to Cisplatin via Suppression of the PI3K-Akt Signaling. Archives of Bio-chemistry &amp; Biophysics, 526, 38-43.  
&lt;br&gt;https://doi.org/10.1016/j.abb.2012.07.003</mixed-citation></ref><ref id="hanspub.36515-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Ye, S.N., Zhang, J.M., Shen, J., et al. (2016) NVP-TAE684 Re-verses Multidrug Resistance (MDR) in Human Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function. British Journal of Pharmacology, 173, 613-626.  
&lt;br&gt;https://doi.org/10.1111/bph.13395</mixed-citation></ref><ref id="hanspub.36515-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Jones, J., Choi, M.Y., Mato, A.R., et al. (2016) Venetoclax (VEN) Mon-otherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. Blood, 128, 637-637.  
&lt;br&gt;https://doi.org/10.1182/blood.V128.22.637.637</mixed-citation></ref><ref id="hanspub.36515-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Yang, Z., Fu, J., et al. (2012) Ethaselen: A Potent Mammalian Thioredoxinreductase 1 Inhibitor and Novelorganoselenium Anticancer Agent. Free Radical Biology and Medicine, 52, 898-908.  
&lt;br&gt;https://doi.org/10.1016/j.freeradbiomed.2011.11.034</mixed-citation></ref><ref id="hanspub.36515-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Xu, L., Lei, J., Jiang, D., et al. (2015) Reversal Effects of Raloxifene on Paclitaxel Resistance in 2 MDR Breast Cancer Cells. Cancer Biology &amp; Therapy, 16, 1794-1801. &lt;br&gt;https://doi.org/10.1080/15384047.2015.1095409</mixed-citation></ref><ref id="hanspub.36515-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Di Pietro, A., Chiaradia-Delatorre, L.D., Gauthier, C., et al. (2014) Quinoxaline-Substituted Chalcones as New Inhibitors of Breast Cancer Resistance Protein ABCG2: Polyspeci-ficity at B-Ring Position. Drug Design Development &amp; Therapy, 8, 609. &lt;br&gt;https://doi.org/10.2147/DDDT.S56625</mixed-citation></ref><ref id="hanspub.36515-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Bisi, A., Gobbi, S., Merolle, L., et al. (2015) Design, Synthesis and Biological Profile of New Inhibitors of Multidrug Resistance Associated Proteins Carrying a Polycyclic Scaffold. Eu-ropean Journal of Medicinal Chemistry, 92, 471-480.  
&lt;br&gt;https://doi.org/10.1016/j.ejmech.2015.01.004</mixed-citation></ref><ref id="hanspub.36515-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Bisi, A., Cappadone, C., Rampa, A., et al. (2017) Coumarin Derivatives as Potential Antitumor Agents: Growth Inhibition, Apoptosis Induction and Multidrug Resistance Reverting Activity. European Journal of Medicinal Chemistry, 127, 577-585. &lt;br&gt;https://doi.org/10.1016/j.ejmech.2017.01.020</mixed-citation></ref><ref id="hanspub.36515-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, J., Wang, R., Lou, L., et al. (2016) Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure-Activity Rela-tionships and Discovery of Promising MDR Reversal Agents. Journal of Medicinal Chemistry, 59, 6353-6369. &lt;br&gt;https://doi.org/10.1021/acs.jmedchem.6b00605</mixed-citation></ref><ref id="hanspub.36515-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Guo, C., Liu, F., Qi, J., et al. (2018) A Novel Synthetic Di-hydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells. Molecules, 23, 3264.  
&lt;br&gt;https://doi.org/10.3390/molecules23123264</mixed-citation></ref><ref id="hanspub.36515-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.Q., Li, J.Y. and Teng, Q.X. (2020) Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers (Basel), 12, 466.  
&lt;br&gt;https://doi.org/10.3390/cancers12020466</mixed-citation></ref><ref id="hanspub.36515-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Ranjbar, S., Khonkarn, R., Moreno, A., et al. (2019) 5-Oxo-Hexahydroquinoline Derivatives as Modulators of P-gp, MRP1 and BCRP Transporters to Overcome Multidrug Resistance in Cancer Cells. Toxicology and Applied Pharmacology, 362, 136-149. &lt;br&gt;https://doi.org/10.1016/j.taap.2018.10.025</mixed-citation></ref></ref-list></back></article>